CT Atlantic AG is a spin-off from the University of Zurich (Zurich, Switzerland) and the Ludwig Institute of Cancer Research (LICR, Zurich, Switzerland and New York, USA). CT Atlantic’s principle focus is the application of human-derived antibodies as anti-cancer therapeutics. The company’s lead programs target CT antigens such as NY-ESO-1 and MAGEA3. CT Atantic was found by Prof. Alexander Knuth, Director of the Department of Clinical Oncology at the University of Zurich. The company is based in Schlieren, Switzerland.
ethris GmbH is a spin out from the Ludwig Maximilians University and the Technical University in Munich. ethris GmbH develops, as the first company world-wide, “Transcript Therapies” based on its proprietary enabling SNIM® RNA designates stabilized, non-immunogenic messenger RNA, an is a first-in-class biopharmaceutical platform for the previously unfeasible repeated administration of messenger RNA. Because of its precursor function, SNIM® RNA leads to sustained protein production within the body and overcomes short duration effects of recombinant proteins. SNIM® RNA has the potential to make mRNA therapeutics a reality in a broad variety of medical indications, from hereditary or acquired metabolic diseases to regenerative medicine.
Magnetovax®, ethris’s second proprietary technology, is an enabling platform for immune-stimulating, nucleic acid-based cancer therapeutics. It is used to localize and activate immune stimulation against tumors directly in tumors by magnetic force. Felovectin, a first in class nanomagnetic gene therapeutic agent, has shown very significant therapeutic benefit in a veterinary clinical trial for the treatment of feline fibrosarcoma, the most frequent skin tumor in cats. Magnetovax®-based nanomagnetic compositions can be used in various cancer indications.
ImmunoQure AG is an emerging biotech company focused on the development of human-derived antibodies for the treatment of inflammation and autoimmune diseases. The scientific founders of ImmunoQure bring multi-disciplinary translational medicine experience to the company enabling the identification and rescuing of autoantibodies against important mediators of human disease. The company is based in Dusseldorf and maintains research operations in Schlieren.
Medovent is a medical device company focused on the development and manufacturing of chitin and chitosan based polymers currently being applied in urological stents, surgical sutures, nerve guides and catheter coatings. Medovent was founded by Dr. Thomas Freier and Dr. Rivelino Montenegro in 2006.
Medoderm GmbH is a Medovent GmbH affiliated company focused on bringing chitosan-based wound dressings to the market.
QLAYM is a highly innovative analytics company. The Q-USD: QLAYM UNSUPERVISED SOLUTION DISCOVERY™ technology identifies predictive systematics in complex data related to a wide range of industrial applications. Qlaym vitalizes data from manufacturing and production to permit the modeling, monitoring and optimization of processes and product development. QLAYM works on both top-line (new products) and bottom-line (robust process management) aspects, for process economics and quality assurance. By unlocking the information trapped in the stream of data from production, engineering, trading, and logistics Qlaym supports their customers to successfully run, optimize, and innovate their business.
Dr. Karsten Henco is founding CEO. Qlaym is based in Düsseldorf and Göttingen, Germany.
Qlaym Healthcare AG
QLAYM Healthcare AG applies the Artificial Intelligence driven technology Q-USD™ to clinical and healthcare data. It is perfectly designed to predict and optimize drug development, study performance and benefit risk evaluation.
Integrative approaches reaching from basic molecular research to pre-clinical, clinical and even post market performances are topics addressed. Q-USD™ enables a detailed, functional and predictive view on therapeutic effects or side effects, molecular disease processes, adaptive clinical tests, novel molecular interconnected pathways, resistances, optimal drug usage for patients according to their personal benefit risk profile, expected patient report outcomes, time to market, and market acceptances. QLAYM Healthcare turns Predictive Medicine into reality.
Dr. Karsten Henco is founding CEO. QLAYM Healthcare is based in Düsseldorf.